Technology Platform

ImmunOs Therapeutics has developed a proprietary platform to generate a novel class of human-derived biologic therapeutics capable of stimulating the innate immune system, thereby leading to an activation of both the innate and the adaptive immune system against cancer and infectious diseases. This is a key advantage over currently available immunotherapeutics, which only focus on the modulation of the adaptive immune system. 

ImmunOs’ platform differentiates by targeting more cells in the tumor than any competing innate immunity technologies with only one single molecule, thereby changing the immune-suppressing tumor microenvironment.

The Company´s technology platform provides carefully screened HLA variants from patients with autoimmune diseases such as ankylosing spondylitis, Crohn’s Disease or psoriasis in order to identify and develop the most promising molecules for the treatment of tumors and other immune diseases. As ImmunOs Therapeutics´ agents are derived from humans, they show a significantly enhanced safety profile.


The Company’s multi-targeting approach is remodeling the tumor microenvironment (TME) – a key prerequisite for immunotherapy to work. This remodeling of the TME occurs in different ways: 

  • First, ImmunOs´ products stimulate the innate immune system directly by activating M1-type macrophages and suppressing M2-type macrophages. Shifting from the M2 to M1-type TME is vital as the M1-type facilitates a robust immune response to tumors. 
  • Second, ImmunOs´ products block immuno-suppressive myeloid-derived suppressor cells (MDSCs), allowing the expansion of killer CD8+ T cells, which can directly destroy cancer. In addition to remodeling the TME, ImmunOs ´products directly stimulate NK-cells which can have a strong anti-tumor effect.

As a result, the Company´s molecules are suited as a monotherapy or in combination therapy to make the environment more amenable to immunotherapy and have demonstrated strong anti-tumor responses in multiple cancer indications in combination with checkpoint inhibitors such as CTLA-4, PD-1, PD-L1, CD47, SIRPα and agonist antibodies such as 4-1BB.

ImmunOs Therapeutics believes that its novel family class of immunomodulators, which stimulate the immune system and increase the efficacy of both checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47, SIRPα) and co-stimulatory agonists (e.g. 4-1BB) in combination therapies will spearhead the next wave of personalized treatments to support patients with a diverse set of cancer indications.